Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthritis.
One hundred and fifty patients with rheumatoid arthritis received 6 mg of auranofin daily for 2-24 months. Thirty patients were withdrawn from the study, and 82 patients were observed for 12 months. Statistical evaluation was available for 74 patients at weeks 24, 38, and 48, respectively. The major side effects observed were diarrhea, rash, and alopecia. Significant improvement was noted in the articular index, ESR, pain, and morning stiffness.
D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006046:Gold / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography
D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold